To evaluate the effects of Tegoprazan on cytotoxicity and NO production in BMMs. Results showed that TEGO significantly inhibited NO production at 100 µg/mL concentration, with cell viability exceeding 80%.
Int J Mol Sci. 2023 Sep 26;24(19):14589
HT-29
10 µM
3 days
To evaluate the mitigating effect of Tegoprazan on indomethacin-induced inhibition of cell proliferation. Results showed that Tegoprazan significantly alleviated the inhibition of cell proliferation induced by indomethacin in HT-29 cells.
Sci Rep. 2024 Nov 8;14(1):27173
Caco-2
10-100 µM
3 days
To evaluate the mitigating effect of Tegoprazan on indomethacin-induced inhibition of cell proliferation. Results showed that Tegoprazan significantly alleviated the inhibition of cell proliferation induced by indomethacin in Caco-2 cells.
Sci Rep. 2024 Nov 8;14(1):27173
HIEC-6
1-100 µM
3 days
To evaluate the mitigating effect of Tegoprazan on indomethacin-induced inhibition of cell proliferation. Results showed that Tegoprazan significantly alleviated the inhibition of cell proliferation induced by indomethacin in HIEC-6 cells.
Sci Rep. 2024 Nov 8;14(1):27173
Caco-2
1.0 mM and 3.0 mM
48 hours
Evaluated the protective effect of Tegoprazan on intestinal epithelial barrier function, showing that Tegoprazan significantly suppressed TNF-a-induced reduction in TEER levels and reduced FITC-dextran flux.
Front Immunol. 2022 May 25;13:870817
Het-1A cells
30 µM
6 hours
To evaluate the effect of Tegoprazan on HCl-induced inflammatory responses. Tegoprazan significantly inhibited HCl-induced pro-inflammatory cytokines (IL-6, IL-8, IL-1β, and TNF-α) but did not significantly affect pyroptosis rate.
Front Immunol. 2024 Dec 16;15:1410904.
Tegoprazan 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6 mice
DNBS and DSS-induced colitis models
Oral
30 mg/kg
Twice daily, throughout the experiment
Evaluated the protective effect of Tegoprazan on colitis, showing that Tegoprazan significantly improved symptoms of DNBS and DSS-induced colitis, including weight loss, colon shortening, and inflammatory cell infiltration.
Front Immunol. 2022 May 25;13:870817
Healthy male subjects
Healthy male subjects
Oral
50 mg
Once daily for 7 days
To evaluate the pharmacokinetics and safety of Tegoprazan when co-administered with atorvastatin. Results showed no significant changes in the systemic exposure of atorvastatin when co-administered with Tegoprazan.
搜索
